Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study

Kobayakawa, Tomonori; Miyazaki, Akiko; Takahashi, J.; Nakamura, Yukio

doi:10.1016/j.bone.2022.116480

Cited by 15 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FRAME study revealed that patients receiving denosumab after 12 months of romosozumab treatment had a sustained reduction in fracture risk and further increase in BMD through the 2-year treatment sequence [ 26 ] and after an additional year of denosumab treatment [ 27 ]. The sequential use of alendronate or ibandronate following romosozumab treatment maintained the BMD at the lumbar spine and total hip [ 24 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis

Tai,

Chen,

Shih

et al. 2024

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis

Tai,

Chen,

Shih

et al. 2024

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

“…BMD decreases shortly after discontinuation of ROMO, underscoring the importance of adequate sequential treatment. 20 In the VICTOR ran-Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current...…”

Section: Efficacy and Safety Of Ibandronate Or Deno For Postmenopausa...mentioning

confidence: 99%

Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)

Rodriguez-Merchan,

Moreno-Garcia,

De la Corte-Rodriguez

2023

SurgiColl

View full text Add to dashboard Cite

Romosumab (ROMO) should be used to treat postmenopausal women with osteoporosis at high fracture risk after carefully considering the cardiovascular status and the risk/benefit balance. Clinicians should avoid ROMO for patients with a history of myocardial infarction or stroke in the past 12 months. Although ROMO offers an alternative for patients with a high risk of osteoporotic fractures, it is affected by previous osteoporosis treatment: using denosumab (DENO) and oral bisphosphonates for over one year attenuates its effect. An additional 12 months of DENO appears to be more effective than ibandronate for the enhancement of bone mineral density (BMD) as a sequential agent after 12 months of ROMO, with few severe adverse events. However, it is important to emphasize that ROMO is not a first-choice medication. It is only indicated when bisphosphonates cannot help, and its clinical use has demonstrated cardiovascular risks. The cost and availability could also make its use problematic in clinical practice. Therefore, although ROMO represents an important advance in the treatment of osteoporosis, it is by no means a solution for osteoporosis.

show abstract

“…In terms of side effects, osteonecrosis of the jaw (ONJ) and atypical femoral fracture are uncommon but serious complications associated with bisphosphonates [ 121 ]. The majority of ONJ cases occur in oncology patients, in whom more frequent and higher dosages are used.…”

Section: Pharmacological Management Of Osteoporosis In Adult-onset Ce...mentioning

confidence: 99%

The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance

Al–Toma

Herman²,

Lems³

et al. 2022

Nutrients

View full text Add to dashboard Cite

Impaired bone mineral density (BMD) is a frequent complication of adult-onset celiac disease (CeD). This is usually due to malabsorption of nutrients, changes in bone metabolism in association with inflammation, and to a lesser extent, decreased overall physical health and mobility. This review aims to highlight the current status concerning surveillance, prevention, and treatment strategies for bone disease in CeD. A practical guidance on these matters is suggested. The available published research on the prevention and treatment of decreased BMD in relation to CeD is scarce. In general, publications were based on expert opinions or extrapolation from studies on postmenopausal women or inflammatory bowel disease. Optimal dietary treatment and an adequate supply of calcium and vitamin D are the cornerstones for the reduction in fracture risk in patients with CeD. In adults with low BMD or fragility fractures, CeD needs to be considered and specifically approached. When osteoporosis is documented, start treatment with an antiresorptive agent; these agents are proven to result in a long-term reduction in fracture risk in high-risk individuals. However, there are some important differences between the management of male and female patients, particularly premenopausal women, that need to be addressed. In patients with persisting diarrhea and malabsorption, parenteral medications may be preferable. Future research specifically focusing on celiac disease and the associated disorders in bone mineralization is mandatory to provide evidence-based recommendations in this field.

show abstract

Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study

Cited by 15 publications

References 27 publications

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis

Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)

The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance

Contact Info

Product

Resources

About